Please login to the form below
mRNA technology
This page shows the latest mRNA technology news and features for those working in and with pharma, biotech and healthcare.
Pfizer/BioNTech initiate study of first mRNA shingles vaccine candidates
Pfizer and BioNTech have announced the start of a phase 1/2 study of their mRNA shingles vaccine candidates. ... a more efficient global production by using mRNA technology.
Latest news
-
AbbVie and Anima Biotech collaborate on mRNA biology modulators
partnership. Jonathon Sedgwick, vice president and global head of discovery research at AbbVie, said: "This collaboration will give AbbVie access to Anima's leading technology platform and deep expertise in mRNA ... Anima’s differentiated approach
-
GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
The tested vaccine candidates produced promising immunogenicity and reactogenicity profiles in ongoing phase 1 clinical programmes for COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. ... new products based on
-
Moderna to acquire OriCiro Genomics for $85m
OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine,” said Stépahane Bancel, chief executive officer of Moderna. ... I am confident that our technology and talent will
-
Novavax initiates phase 2 combination COVID-19/flu vaccine study
In November 2022, Pfizer and BioNTech also initiated a phase 1 study of their mRNA-based combination COVID-19/influenza vaccine. ... which are based on BioNTech’s proprietary mRNA platform technology.
-
mRNA technology for universal flu vaccine shows early promise in US study
The two-dose vaccine uses the same mRNA technology used in successful COVID-19 vaccines, delivering tiny lipid particles containing mRNA instructions for cells to create replicas of haemagglutinin proteins that ... It would be comparable to
More from news
Approximately 6 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
After the wildfire: how will healthcare recover from the pandemic?
Some of the ‘early regrowth’ is also already familiar, with telemedicine, decentralised clinical trials and mRNA as a drug technology platform being prime examples. ... In particular, the idea that contact between health consumers and healthcare
-
Deal Watch March 2017
In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)
-
Deal Watch June 2016
Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... The mRNA vaccines will also be assessed in
-
Deal Watch November 2015
Sanofi will gain access to BioNTech's mRNA formulation technology to generate new cancer immunotherapies. ... Dermatology focused R&D company with formulation technology and 3 clinical stage projects.
-
Pharma deals during March 2013
In its $420m five-year alliance with Moderna Therapeutics, AZ is making an upfront payment of $240m for the discovery of messenger RNA (mRNA) therapeutics. ... 545. Moderna Therapeutics/ AstraZeneca. Development &commercialisation. mRNA technology for
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
CureVac’s CEO appointed to EC High Level Group
Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... Governing board member of the European Institute
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
How to innovate and influence people in times of misinformation
but that thanks to new mRNA technology, vaccine prototypes would be ready for trials within weeks and the first shots would go into arms before the end of 2020, what would ... Considering what else is in the technology pipeline, that should give us all
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
to use mRNA vaccine technology and among the first to use viral vectors,. ... 6. Komaroff A. Why are mRNA vaccines so exciting? Harvard Health.December 2020.
-
Is the world ready for a COVID-19 vaccine?
A few of the coronavirus vaccines being trialled use “messenger” RNA (mRNA) technology. ... In time, some of these challenges may be overcome, for example, if the technology used for mRNA vaccines advances to allow them to be stored at higher
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- The state of pharma customer experience
- GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
